Green, Schafle & Gibbs has launched an investigation into the alleged Ponzi Scheme operated by Philadelphia-area stockbroker Paul W. Smith. Based in Wayne, PA, Smith operated a long-running Ponzi Scheme using purported investments in The Haverford Group, which costs a group of mostly retired and elderly investors approximately $2.35 million, according to the SEC.
There’s a universe of advice and information out there for investors looking to educate and protect themselves. Tune in to MSNBC or visit TheStreet.com and you’ll find a million answers to million different questions related to investing intelligently. But for all this “noise” about investing, there is some basic, critical information you probably will not hear about that could make all the difference to your financial well-being.
Getting hip implant surgery these days is easy enough. Unfortunately the problems tend to start after the procedure, when many patients notice symptoms and side-effects related to defective hip implant technology. In some cases, the technology is so dangerous - and causes so much pain - that hip implant revision surgery becomes necessary. In such cases, you may need to explore your legal rights.
In a notable FINRA arbitration award released late last month from a Philadelphia, Pennsylvania Arbitrator. Philadelphia-based FINRA attorney arbitration law firm, Green, Schafle & Gibbs, has secured a more than $63,000 arbitration award from brokerage firm Morgan Stanley Smith Barney to an investor who had sought $80,000 in financial damages.
A bellwether trial on October 23, 2017 will structure arguments for future matters pertaining to faulty IVC filter devices. This case is relevant for victims of faulty IVC filters because it will determine whether the manufacturer was negligent in selling and producing a product that has allegedly caused a number of injuries and fatalities.
In 2010, the FDA issued a safety warning over inferior vena cava (IVC) filters, a type of vascular filter implanted into the heart by radiologists or surgeons in order to presumably prevent life-threatening pulmonary emboli (PEs). In the years following the warning, the rate of implantation slowed, although it is still more than 10x higher than in Europe.